Common VKORC1 and GGCX polymorphisms associated with warfarin dose (Q34417386)

2 August 2017

title

Common VKORC1 and GGCX polymorphisms associated with warfarin dose (English)

1 reference

2 August 2017

1 reference

5

1 reference

2 August 2017

11

1 reference

2 August 2017

O Wallerman

7

0 references

Mia Wadelius

1

object named as

M Wadelius

1 reference

2 August 2017

L Y Chen

2

1 reference

2 August 2017

K Downes

3

1 reference

2 August 2017

J Ghori

4

1 reference

2 August 2017

N Eriksson

6

1 reference

2 August 2017

H Melhus

8

1 reference

2 August 2017

C Wadelius

9

1 reference

2 August 2017

D Bentley

10

1 reference

2 August 2017

language of work or name

1 reference

1 January 2005

1 reference

The Pharmacogenomics Journal

2 August 2017

published in

1 reference

2 August 2017

volume

5

1 reference

2 August 2017

issue

4

1 reference

2 August 2017

page(s)

262-270

1 reference

Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance.

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500313

Yoga in treatment of carpal-tunnel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500313

Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500313

Pharmacogenetics of CYP2C9 and interindividual variability in anticoagulant response to warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500313

Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500313

Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500313

Adverse drug events and medication errors in Australia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500313

Interindividual variability in sensitivity to warfarin--Nature or nurture?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500313

Pharmacogenetics and anticoagulant therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500313

Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500313

Relative impact of covariates in prescribing warfarin according to CYP2C9 genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500313

Pharmacogenetics of oral anticoagulants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500313

Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500313

Pharmacogenetics of warfarin elimination and its clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500313

Human P450 metabolism of warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500313

CYP2C9 allelic variants: ethnic distribution and functional significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500313

The frequency and effects of cytochrome P450 (CYP) 2C9 polymorphisms in patients receiving warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500313

Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500313

Medicine: K is for koagulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500313

Genetic mechanisms for hypersensitivity and resistance to the anticoagulant Warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500313

Characterization and purification of the vitamin K1 2,3 epoxide reductases system from rat liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500313

Homozygosity mapping of a second gene locus for hereditary combined deficiency of vitamin K-dependent clotting factors to the centromeric region of chromosome 16.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500313

Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500313

Identification of the gene for vitamin K epoxide reductase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500313

Compound heterozygous mutations in the gamma-glutamyl carboxylase gene cause combined deficiency of all vitamin K-dependent blood coagulation factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500313

Purification of vitamin K-dependent carboxylase from cultured cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500313

Isolation of the human gamma-carboxylase and a gamma-carboxylase-associated protein from factor IX-expressing mammalian cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500313

Chromosomal localization of the gamma-glutamyl carboxylase gene at 2p12.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500313

The structure of haplotype blocks in the human genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500313

A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500313

Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and gamma-glutamyl carboxylase) gene variants with warfarin sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500313

Pedigree disequilibrium tests for multilocus haplotypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500313

Linkage disequilibrium in humans: models and data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500313

Intracranial traumatic and non-traumatic haemorrhagic complications of warfarin treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500313

7 January 2021

Hemorrhagic complications of anticoagulant treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500313

7 January 2021

Mechanism of action of warfarin. Warfarin and metabolism of vitamin K 1

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500313

7 January 2021

Pharmacodynamic resistance to warfarin associated with a Val66Met substitution in vitamin K epoxide reductase complex subunit 1.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500313

7 January 2021

Microsomal vitamin K-dependent carboxylase

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500313

7 January 2021

Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500313

7 January 2021

Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500313

7 January 2021

Identifiers

DOI

10.1038/SJ.TPJ.6500313

1 reference

Dimensions Publication ID

2 August 2017

1031034545

0 references

1 reference